mynth
03/2026Majority

MTIP takes majority stake in Verifarma

SPAIN Software / Industry-Specific Software / Healthcare REV €5–25M

Context

MTIP has completed a majority strategic investment in Verifarma, a Spain,headquartered software provider. The transaction is designed to propel the next phase of the company's growth, with a specific focus on international scaling and technological advancement. All four co,founders, including the CEO, CFO, COO, and Chief AI Officer, will continue to lead the business post,investment, ensuring management continuity and the preservation of long,term customer relationships. The strategic rationale for the partnership involves significant investment in the core track,and,trace technology platform and the expansion of AI,driven quality management features. Furthermore, the capital will be used to strengthen the group's go,to,market infrastructure in Europe and to further penetrate the Latin American market. This investment aligns with the growing global demand for rigorous pharmaceutical traceability and regulatory compliance, positioning the organization as a leading international player in the healthtech space. MTIP intends to leverage its extensive experience in scaling healthcare technology companies to support the entity's continued internationalization and platform development.

Verifarma, which reported an EBITDA margin of [members only] in 2025, is valued in this transaction at an EV/EBITDA multiple of [members only].

-> Deep-dive in TMT (Tech, Media, Telecom) market trends

Target

Verifarma is a high, growth SaaS provider specializing in integrated serialization, traceability, and regulatory compliance solutions tailored for the pharmaceutical industry. The organization provides an end,to,end software platform that supports pharmaceutical manufacturers, wholesalers, and distributors in navigating complex global traceability requirements. Its technology spans the entire supply chain, ensuring the safety and authenticity of medicines by tracking products from production to the end consumer. Established in 2007, the entity has developed a leading position in the Latin American market and is rapidly expanding its footprint across Europe. With a mission focused on supply chain integrity, the company serves a diverse global client base, leveraging AI,driven capabilities to enhance quality management and track,and,trace efficiency for more than 2,000 companies.

Ent. Value

[members only]

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

[members only]

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2025
€5–25M
€0–5M
[members only]
2024
€5–25M
€0–5M
[members only]

Similar deals in Software

Similar deals in Software
DateAcquirerTargetCountrySector
04/2026ATHOS CONSORTIUM / A.P. MOLLER HOLDINGDOCTOLIBFRANCEHealthcare
04/2026RELXDOCTRINEFRANCEIndustry-Specific Software
03/2026TOTAL SPECIFIC SOLUTIONS (TSS)CYBERJETFRANCEDefense & Aerospace
03/2026ASMODEE GROUPATM GAMINGFRANCEGaming & Consumer Apps
03/2026MANAGEMENT & PRIVATE INVESTORSMASA GROUPFRANCEDefense & Aerospace
03/2026MANAGEMENT & PRIVATE INVESTORSRIVALIS-HENRRIFRANCEERP, HR & Finance
03/2026NORVESTORZALARISNORWAYERP, HR & Finance
03/2026MAIN CAPITAL PARTNERSGINGCO SYSTEMSGERMANYCollaboration & Productivity
03/2026INSIGHT PARTNERSWONDERFULNETHERLANDSData, Analytics & AI
03/2026AXCELGEOMATIKKNORWAYIndustry-Specific Software

REFERENCES

Revenue range: REV €5–25M

EBITDA range: €0–5M

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Verifarma by MTIP are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: verifarma

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Verifarma, a Spanish company specialised in Industry-Specific Software, by MTIP in 2026.

What were Verifarma’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Verifarma generated annual revenue estimated in the €5–25M range and EBITDA in the €0–5M bracket (FY 2025). Detailed financial figures are available to members.

What sources support the information on this transaction?

Transaction intelligence is supported by independent reporting from specialized financial publications, alongside a private document shared by the community and verified by the mynth team to ensure the accuracy of the shared information.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.